glp-1 agonists brands Market to Reach $170.75B by 2033 | Mayuri Lamba posted on the topic The glucagon-like peptide 1 receptor

Hunter, D

Biological actions and therapeutic potential of the glucagon-like peptides

The use of prazosin, an 1-adrenergic receptor blocker, showed that the ability of GLP-1RAs to reduce TNF- in plasma was disrupted, signifying the vital role of 1-adrenergic receptors in the anti-inflammatory action of GLP-1RAs

Recent evidence suggests that their pleiotropic effectsbeyond glycemic control and weight lossinclude anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease

[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Sachse A., Wolf G

Talk to a licensed healthcare provider before starting, stopping, or changing any treatment